Protagenic Therapeutics Inc (PTIXW) Stock Analysis

Protagenic Therapeutics Inc (PTIXW) is a publicly traded company in the HEALTHCARE sector. It trades at $0.00. This page summarizes the public market data, fundamentals, and frequently asked questions for PTIXW, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Protagenic Therapeutics Inc

Protagenic Therapeutics, Inc. (PTIXW) is a forward-looking biopharmaceutical company headquartered in New York, dedicated to developing innovative therapies for stress-related mood and neuropsychiatric disorders. With a focus on addressing significant unmet medical needs in mental health, Protagenic applies its deep expertise in neurobiology to identify and develop novel treatment solutions that may enhance patient outcomes. The company's robust research initiatives are focused on exploring g...

GNG Research Analysis

GNG Research scores Protagenic Therapeutics Inc (PTIXW) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PTIXW.

Frequently Asked Questions

Does PTIXW pay dividends?

Protagenic Therapeutics Inc (PTIXW) does not currently pay a regular dividend.